Plasma IQ is the latest advancement in aesthetics and the first FDA Class II cleared handheld plasma device. The device delivers focused, controlled plasma energy to safely and effectively create ...
An in-depth look at how Turkey’s top clinics use next-generation technology to deliver superior results at globally competitive prices.
The novel radiotracer ¹⁸F-FAPI-RGD in PET/CT scans shows potential for diagnosing ILD in connective tissue disease patients by highlighting fibroblast activation and tissue remodeling. Patients with ...
This article is based on a poster originally authored by Fiona Leslie, Chloe Whiting, and Megan Webster. TGF-β1-mediated activation of fibroblasts, their transition to α-SMA-expressing myofibroblasts, ...
HOUSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a ...
The aggregate gross proceeds to the Company from the offering are expected to be approximately $1.7 million, before deducting placement agent’s fees and other offering expenses payable by the Company.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback